Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial
In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placeboAdmilparant demonstrated a
Bristol Myers Squibb's medicine worked better than placebo in a lung disease test. When a company wins a big drug trial like this, it hints at future sales and product strength.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.